Pantovigar - a high effective product designed primarily for the treatment of diffuse hair loss in women as well as for the treatment of damaged hair, in the combined therapy can be successfully applied in other types of alopecia.

The purpose of this study is to evaluate efficacy and tolerability of combination therapy Pantovigar plus 2% minoxidil vs 2% minoxidil. To collect tolerability data for combined treatment Pantovigar plus 2% Minoxidil course therapy.

Inclusion Criteria:

• Female patient complaint of hair loss and/or hair density reduction for more than 3 months.
• More than 15 % of telogen frontoparietal hair as shown in the phototrichogram.

Exclusion Criteria:

• Symptomatic diffuse alopecia (screening for iron and thyroid function, thyroid stimulating hormon, triiodothyrine, ferritin , total iron-binding capacity)
• Active or history of systemic autoimmune disease, e.g. lupus erythematodes etc.
• Hyperandrogenic alopecia (polycystic ovary syndrome, adrenogenital syndrome, tumors with androgenic activity) (testosterone, prolactin hormone, androstenedione, dehydroepiandrosterone)
• Initiation or termination of hormone therapy within 6 months prior to entering study
• Hormone therapy with androgenic action, e.g. norethisterone etc.
• Pregnancy or lactation within 6 months prior to entering study
• Alopecia areata
• Scarring alopecia
• Treatment with hair promoting agent within 3 months prior to entering study
• Known hair loss after drug intake
• Concomitant use of the drugs causing a hair loss (e.g. aromatase inhibitors, thyreostatics, cytostatics, etc,)